Cite
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
MLA
Surti, Toral S., et al. “Randomized Controlled Trial of the Glycine Transporter 1 Inhibitor PF-03463275 to Enhance Cognitive Training and Neuroplasticity in Schizophrenia.” Schizophrenia Research, vol. 256, June 2023, pp. 36–43. EBSCOhost, https://doi.org/10.1016/j.schres.2023.04.010.
APA
Surti, T. S., Ranganathan, M., Johannesen, J. K., Gueorguieva, R., Deaso, E., Kenney, J. G., Krystal, J. H., & D’Souza, D. C. (2023). Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research, 256, 36–43. https://doi.org/10.1016/j.schres.2023.04.010
Chicago
Surti, Toral S., Mohini Ranganathan, Jason K. Johannesen, Ralitza Gueorguieva, Emma Deaso, Joshua G. Kenney, John H. Krystal, and Deepak Cyril D’Souza. 2023. “Randomized Controlled Trial of the Glycine Transporter 1 Inhibitor PF-03463275 to Enhance Cognitive Training and Neuroplasticity in Schizophrenia.” Schizophrenia Research 256 (June): 36–43. doi:10.1016/j.schres.2023.04.010.